Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment
Journal of Controlled Release · 2025-12 · 388 · 114367
DOI: 10.1016/j.jconrel.2025.114367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-12. Verfasst von Danqi Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging& Interventional Radiology, Department of Radiology, Zhongda Hospital, Medical…. Hauptthemen laut MEDLINE: Glioblastoma, Hepatitis A Virus Cellular Receptor 2, Epirubicin, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB), particularly anti-programmed cell death protein 1 blockade (aPD-1), has demonstrated limited efficacy in glioblastoma (GBM) due to the tumor's highly immunosuppressive microenvironment and the restrictive blood-brain barrier (BBB). T cell immunoglobulin and mucin domain-3 (TIM-3), an emerging immune checkpoint widely expressed on various immune cells beyond just exhausted T cells, presents a promising target for GBM treatment. In this study, we engineered A2-TELM, a pH-sensitive macrophage membrane-coated nanoparticle conjugated with angiopep-2 peptide, to deliver anti-TIM-3 antibody (aTIM-3) alongside immunogenic cell death (ICD)-inducing agent Epirubicin (EPI) to brain tumors. This system achieves efficient BBB penetration and precise tumor targeting, enabling effective drug distribution and sustained presence within the tumor microenvironment. A2-TELM significantly reshapes the tumor immune microenvironment by initiating ICD, enhancing both the innate and adaptive immune response, with CD8+ T cells and macrophages essential for its anti-tumor function. This effectively inhibits GBM tumor growth, prolongs mice survival, and induces durable anti-tumor immune memory. Notably, aTIM-3 showed stronger anti-tumor effects than aPD-1 when combined with EPI in several GBM models, largely through enhanced macrophage polarization and phagocytic activity. Overall, this targeted system, which leverages chemotherapy-induced ICD to improve TIM-3 anti-tumor efficacy, holds substantial promise as a therapeutic strategy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging& Interventional Radiology, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
- Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, 210009, Jiangsu, China.
- Department of Biochemistry and Molecular Biology Medical School of Southeast University, Nanjing, 210009, Jiangsu, China.
- Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging& Interventional Radiology, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.. Electronic add…
Förderung
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhu, D., Zhu, Y., Yang, X., Gao, L., Zhang, Z., Xu, X., Dong, L., Zhang, H., Yun, Z., Yang, H., Ju, S., Gu, X., & Xie, J. (2025). Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment. Journal of Controlled Release, 388, 114367. https://doi.org/10.1016/j.jconrel.2025.114367
Vancouver
Zhu D, Zhu Y, Yang X, Gao L, Zhang Z, Xu X, et al. Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment. Journal of Controlled Release. 2025;388:114367. doi:10.1016/j.jconrel.2025.114367
BibTeX
@article{Zhu2025,
author = {Zhu, Danqi and Zhu, Yini and Yang, Xuhong and Gao, Lin and Zhang, Zhiqi and Xu, Xiaoxuan and Dong, Lei and Zhang, Haoge and Yun, Zhengcheng and Yang, Hui and Ju, Shenghong and Gu, Xiaochun and Xie, Jinbing},
title = {Enhancing TIM-3 immunotherapy with epirubicin-loaded pH sensitive fusion membrane nanoparticles for effective glioblastoma treatment},
journal = {Journal of Controlled Release},
year = {2025},
volume = {388},
pages = {114367},
doi = {10.1016/j.jconrel.2025.114367}
}
EUVIMED